PORCINE CYTOMEGALOVIRUS (PCMV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Porcine cytomegalovirus (PCMV), also known as suid betaherpesvirus 2 (SuBHV2), is a betaherpesvirus in the family Orthoherpesviridae that causes inclusion body rhinitis in young pigs. PCMV is ubiquitous in pig populations worldwide, with herd prevalence exceeding 90% and individual animal prevalence over 98% in Europe, North America, and Japan. The virus was originally identified based on the pathognomonic histopathological finding of basophilic intranuclear inclusion bodies in cytomegalic cells of the nasal mucosa. Clinical disease is rare in immunologically mature pigs but can be severe or fatal in fetuses and neonates, causing systemic disease with high mortality. In older pigs, infection is typically subclinical or produces mild rhinitis, though PCMV has been associated with the porcine respiratory disease complex (PRDC) and shows significant correlation with PCV2 coinfection. The virus establishes latent infection with potential for reactivation. PCMV has gained attention as a xenotransplantation safety concern given its detection in tissues of primates receiving porcine xenografts and recent detection in the first human recipient of a genetically modified pig heart transplant. No vaccines or specific treatments are available, and the virus's ubiquitous distribution makes elimination from commercial herds impractical without specialized early weaning and barrier rearing protocols.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
No naturally acquired human PCMV infections have been reported through any route, including foodborne transmission. PCMV infection is limited to pigs under natural conditions—the virus does not replicate in mice, rabbits, dogs, cattle, or chicken embryos. Despite the ubiquitous presence of PCMV in pig populations globally and extensive human consumption of pork products, no foodborne transmission pathway has been identified. The xenotransplantation concerns relate to direct tissue/organ transplantation from pigs to immunosuppressed humans, not food consumption.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
No natural human PCMV infections have been documented. The virus exhibits strict host specificity under normal conditions. Concerns about PCMV center on xenotransplantation: virus replication has been detected in tissues of baboons receiving porcine heart or composite thymokidney xenotransplants, and PCMV was detected in peripheral blood mononuclear cells of the first human recipient of a genetically modified pig heart in 2022. However, pig-to-primate islet xenotransplantation studies found no evidence of PCMV transmission. In vitro studies showed PCMV could infect human fibroblasts, raising theoretical concerns. These findings are relevant for the specialized context of xenotransplantation in immunosuppressed recipients but do not indicate zoonotic risk for farm workers, veterinarians, or the general public under normal occupational or consumer exposure conditions.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
PCMV is transmitted horizontally via the oronasal route, with infection most commonly occurring perinatally in commercial pig holdings. Vertical (congenital) transmission is also well documented. The virus is shed in nasal and ocular discharge, urine, and cervical fluid. The majority of pigs shed PCMV in nasal secretions between 3 and 8 weeks of age, indicating infection is typically acquired by contact within the infected cohort—piglets infect each other. Virus shedding from primary infection lasts 10-30 days, and congenitally infected pigs excrete virus until death. Latent infection with potential reactivation means recovered pigs can resume shedding. Given that >90% of herds and >98% of individual pigs are infected, standard biosecurity measures cannot prevent PCMV transmission in commercial settings—the virus is already present in virtually all source populations. Elimination requires specialized protocols: cesarean derivation and barrier rearing of neonatal pigs can produce PCMV-free populations, but this is only practical for specific purposes such as xenotransplantation donor herds, not commercial production.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
Clinical disease in neonates presents with recognizable signs: respiratory distress (sneezing, nasal discharge, coughing, dyspnea), depression, anorexia, and occasionally neurological disease. A black discoloration around the eyes from conjunctival discharge is characteristic. In fetuses and neonates, systemic infection causes distinctive pathology. The histopathological hallmark is pathognomonic: basophilic intranuclear inclusion bodies with cytomegaly and karyomegaly in nasal mucous glands, Harderian and lachrymal glands, renal tubular epithelium, and (in neonates) capillary endothelium of lymphoid tissues. Laboratory confirmation uses virus isolation in porcine cells (primary lung cells, PK-15, porcine turbinate), PCR assays for viral DNA detection, and serology (ELISA with IgG/IgM differentiation, IFA). Note that in utero infected piglets do not seroconvert—antibody testing is not reliable for congenital infections. The combination of high prevalence and pathognomonic histopathology makes diagnosis straightforward when disease occurs; the challenge is that most infections are subclinical.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
PCMV causes a spectrum of losses depending on the age and immune status of affected pigs. In naive herds with congenital or neonatal infection, morbidity is 100% and mortality can reach 10% baseline, increasing to 50% with secondary bacterial or viral infections. Fetuses infected in utero suffer embryonic death, infertility, and stillbirths—pregnant sows may excrete virus in cervical fluids concomitant with fetal deaths. Neonatal piglets develop fatal systemic disease with generalized lesions affecting lymphoid tissues, lungs, kidneys, and CNS. In older pigs, infection is usually subclinical to mild and self-limiting, but PCMV has been significantly associated with porcine respiratory disease complex (PRDC) and shows correlation with PCV2 coinfection that may exacerbate respiratory disease severity. The ubiquitous nature of PCMV means these losses occur as ongoing endemic disease rather than epidemic outbreaks—chronic, distributed losses across the industry rather than acute catastrophic events.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
PCMV is not an OIE/WOAH-listed disease and does not trigger trade restrictions. The virus is ubiquitously present in pig populations worldwide—essentially all trading partners have endemic PCMV, eliminating any basis for trade discrimination. There are no regulatory notifications or movement controls associated with PCMV detection. Consumer awareness of PCMV is negligible, and the virus poses no recognized food safety concern. Market impacts are limited to the production losses described above, which represent chronic endemic costs absorbed into production economics rather than acute market disruption events. The primary regulatory/market relevance of PCMV relates to xenotransplantation, where PCMV-free status of donor animals is a safety requirement—a specialized niche market rather than mainstream pork production.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PCMV is a DNA virus (betaherpesvirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns regardless of disease epidemiology or management approaches.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for PCMV, and none are used in pig production. Antimicrobials may be used to address secondary bacterial infections in PCMV-affected neonates or in pigs with PRDC where PCMV is a contributing factor, but PCMV-specific management does not involve antimicrobial use. The virus's ubiquitous distribution and lack of available interventions mean there is no PCMV-specific treatment protocol that could drive antimicrobial selection pressure.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments are available for PCMV infection in any species. Management of affected neonates is limited to supportive care, which has minimal efficacy given the rapid, severe course of systemic disease. In older pigs where infection is typically subclinical or mild, treatment is unnecessary as disease is self-limiting. There are no approved therapeutics and no treatment protocols that alter disease outcome. Prevention of neonatal infection through management of sow exposure timing (ensuring piglets acquire maternal antibodies before exposure) is the only available intervention strategy.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No vaccines are available for PCMV. The ubiquitous distribution of the virus (>90% herd prevalence) and typically subclinical nature of infection in older pigs have not created sufficient market demand for vaccine development. Maternal antibodies provide some protection to piglets and are the primary mechanism limiting neonatal disease in endemic herds—sows in infected herds transfer antibodies that persist approximately 2 months. However, virus shedding occurs even in the presence of maternal antibodies, indicating incomplete protection. Development of PCMV vaccines has not been prioritized given the limited clinical impact in commercial settings and the technical challenges of betaherpesvirus vaccinology.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
PCMV eradication from commercial pig populations is not feasible given the virus's ubiquitous distribution (>90% herd prevalence, >98% individual prevalence), efficient horizontal and vertical transmission, establishment of latent infection, and lack of vaccines or treatments. The virus can be eliminated from specialized populations using cesarean derivation and barrier rearing of neonatal pigs—protocols developed for xenotransplantation donor herds—but these are impractical for commercial production at scale. Unlike PRV, there is no DIVA vaccine system to enable identification and removal of infected animals from vaccinated populations. The economic impact of PCMV in commercial production (primarily neonatal losses in naive herds, contribution to PRDC) does not justify the extraordinary measures that would be required for eradication. PCMV will remain an endemic, ubiquitous infection in commercial pig populations indefinitely.